{"commentary":{"count":96,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":40,"youtube":31,"podcast":23,"x_video":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04824092\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"frontMIND","nct_id":"NCT04824092","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=frontmind-nct04824092. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"frontMIND","arms":[{"description":"Patients will receive tafasitamab plus lenalidomide in addition to R-CHOP for six 21-day cycles:\n\nTafasitamab dose: 12 mg/kg body weight. Each 21-day cycle (cycles 1-6) will comprise of a tafasitamab IV infusion on Day 1, Day 8 and Day 15.\n\nLenalidomide dose: 25 mg as a starting dose per os (orally) once per day on Days 1-10 of each 21-day cycle\n\nR-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle","label":"Tafasitamab plus lenalidomide in addition to R-CHOP","type":"EXPERIMENTAL"},{"description":"Patients will receive tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP for six 21-day cycles:\n\nTafasitamab placebo: 0.9% saline solution Days 1, 8 and 15 of each 21-day cycle\n\nLenalidomide placebo: Days 1-10 of each 21-day cycle\n\nR-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle","label":"Tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-11-01","type":"ESTIMATED"},"conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":{"count":899,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tafasitamab","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Rituximab","type":"DRUG"},{"name":"Cyclophosphamide","type":"DRUG"},{"name":"Doxorubicin","type":"DRUG"},{"name":"Vincristine","type":"DRUG"},{"name":"Prednisone","type":"DRUG"},{"name":"Tafasitamab placebo","type":"DRUG"},{"name":"Lenalidomide placebo","type":"DRUG"}],"last_update":"2026-04-01","lead_sponsor":"Incyte Corporation","official_title":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-09-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"PFS-INV","timeFrame":"Time from date of randomization until Progressive Disease or death from any cause. In this trial, the primary endpoint is PFS as assessed by the investigator (up to 43 months)"}],"references":[{"citation":"Lenz G, Trneny M, Burke JM, Nowakowski GS, Fox CP, Chiappella A, Duell J, Jeon YW, Cheah CY, Westin J, Ye JZ, Caguioa PB, Belada D, Shin HJ, Oh SY, Amorim S, Ku M, Mocikova H, Jimenez JL, Gaidano G, Rosenwald A, Chiarle R, Colucci P, Ioannidis S, Cheng L, Vitolo U; frontMIND Study Investigators. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026 Jun 20;407(10547):2528-2541. doi: 10.1016/S0140-6736(26)00866-4. Epub 2026 May 30.","pmid":"42217458","type":"DERIVED"},{"citation":"Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Roost Clausen M, Ludvigsen Al-Mashhadi A, Schou Pedersen R, Poulsen CB, Gang AO, Brown P, El-Galaly TC, Stauffer Larsen T. International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma. Clin Lymphoma Myeloma Leuk. 2026 Jan;26(1):e62-e76. doi: 10.1016/j.clml.2025.08.020. Epub 2025 Sep 3.","pmid":"40993016","type":"DERIVED"},{"citation":"Duell J, Westin J. The future of immunotherapy for diffuse large B-cell lymphoma. Int J Cancer. 2025 Jan 15;156(2):251-261. doi: 10.1002/ijc.35156. Epub 2024 Sep 25.","pmid":"39319495","type":"DERIVED"},{"citation":"Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, Andre M, Persona EP, Pichler P, Staber PB, Trneny M, Duell J, Waldron-Lynch M, Wagner S, Mukhopadhyay A, Dirnberger-Hertweck M, Burke JM, Nowakowski GS. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood. 2023 Oct 19;142(16):1348-1358. doi: 10.1182/blood.2023020637.","pmid":"37369099","type":"DERIVED"}],"start_date":{"date":"2021-05-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","url":"https://clinicaltrials.gov/study/NCT04824092"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/frontmind-nct04824092"}